Introduction
Benign prostatic hyperplasia (BPH) is a common disorder in ageing men; between the ages of 50 and 60 y 50% of men develop this disorder 1 and 50% of these men have clinically signi®cant symptoms requiring treatment. 2 BPH is a progressive enlargement of the prostate associated with a collection of changes which include voiding disturbance, prostatic enlargement and urodynamic obstruction, 3 Although lower urinary tract symptoms (LUTS) are suggestive of infravesical obstruction (IVO), they are not speci®c to BPH and therefore certain diagnostic tests may be necessary to con®rm obstruction. The 4th International Consultation on BPH made recommendations on the types of evaluation necessary to determine whether a patient's symptoms are due to IVO associated with BPH. 4 These include the following assessments: renal function; serum prostate-speci®c antigen (PSA) levels; urinary¯ow rate; and post-void residual urine volume. In assessing IVO, each of these methods has certain drawbacks. For example, uro¯owmetry has the advantage of being a non-invasive technique; however it is an indirect measure of obstruction and suffers from a lack of reproducibility. 5 Measurement of post-void residual urine may also be misleading, since large residual volumes can result from bladder hypocontractility as well as IVO. For these reasons, a greater role for urodynamic evaluation in men with LUTS secondary to BPH has been suggested. 6 Pressure-¯ow studies are necessary for the reliable urodynamic diagnosis of IVO in BPH patients. Although the procedures are invasive, involving urethral catheterisation, urodynamic testing involves little risk and complications are rare. 4 The basis for all pressure-¯ow studies is the recording of the pressure-volume loop, which starts with the onset of¯ow, continues to the maximum¯ow rate, and ends with the termination of¯ow. The most relevant parameters include opening pressure at the start of¯ow and detrusor pressure (DP) at maximum¯ow. DP at maximum¯ow is the measurement most closely associated with the assessment of IVO, and greater diagnostic accuracy can be obtained by relating it to the maximum ow rate (Q max ). 5 Increased interest in the management of BPH has stimulated research into new treatments as well as further critical evaluation of existing therapies, the use of which has developed more in recent years. Clinical studies have mainly assessed the effectiveness of medical treatments for BPH through the measurement of modi®cations in symptoms, maximum¯ow, residual volume and prostate size. 7, 8 However, using these parameters it is not always possible to de®ne the degree of IVO. In pressure-¯ow studies, urinary¯ow rate and the DP required to achieve this¯ow rate are measured simultaneously; this is the reference test for IVO, which is characterised by a combination of low urinary¯ow rate and high DP. 9 However, despite the fact that these measurements more accurately re¯ect changes in IVO, 4 relatively few studies have examined urodynamic changes during BPH treatment.
Prostatic growth is dependent on androgens 10 and androgen-inhibition is therefore a rational therapeutic option in the treatment of BPH. In the prostate gland, the activity of testosterone is greatly increased by its reduction to dihydrotestosterone (DHT) by the 5a-reductase isoenzymes type 1 and type 2. The lipido-sterolic extract of Serenoa repens (Permixon 1 *) used in a number of countries as a ®rst-line treatment for BPH is a noncompetitive inhibitor of both 5a-reductase type 1 and type 2. This inhibition has recently been con®rmed in vitro in a novel co-culture model of BPH 11 and in vivo in prostate tissue from patients treated with Permixon 1 for 3 months. 12 Permixon 1 also has anti-proliferative and anti-in¯ammatory activities: it has been demonstrated to inhibit basic ®broblast growth factor (bFGF)-and epidermal growth factor (EGF)-induced proliferation 13 and the production of in¯ammatory mediators 14 in cultured human prostate cells. Additionally, studies show that Permixon 1 improves symptoms and urinary¯ow rates in BPH, is well tolerated, and has a comparable clinical ef®cacy to that of a-blockers 15 and a synthetic 5a-reductase type 2 inhibitor (®nasteride). 16 Unlike other 5a-reductase inhibitors, Permixon 1 does not affect PSA secretion, thus permitting measurement of PSA levels for prostate cancer screening. 11 Due to a lack of urodynamic data from BPH patients, the present pilot study was performed to evaluate the urodynamic and symptomatic impact of Permixon 1 in the treatment of patients with BPH.
Materials and methods

Design
A total of 75 patients were included in this prospective, controlled study, of which 57 received Permixon 1 160 mg twice daily (morning and evening) for 9 weeks. The control group (n 18) did not receive any medical treatment for BPH. Although patients were not randomised into the study groups, pre-treatment urodynamic parameters in each group were similar.
The trial was authorised by the local ethics committee and informed consent was obtained in advance from participating patients.
Patients
Patients were included in the study if they had mild/ moderate BPH according to their mean International Prostate Symptom Score (I-PSS) (`19 points). Other inclusion criteria included a residual urine volume of 100 ml, maximum urinary¯ow (Q max ) of 5 ± 15 ml/s, and no indications for acute or emergency BPH treatment.
Exclusion criteria were the presence of urinary tract infections, suggestion of prostate cancer (PSA b 6 ng/ml), urological disease affecting micturition (eg stones and urethral strictures), previous urological surgery (including the prostate, bladder and urethra), testicular surgery, detrusor instability, unstable or neurogenic bladder, concomittant neurogenic disease and renal or liver insuf®-ciency. Patients were also excluded if they were taking concomittant medication that might interfere with study medication, including other 5a-reductase inhibitors, a-or b-blockers, barbiturates and antidepressants. 
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the end of the 9-week treatment period. This included freē ow uro¯owmetry, measurement of post-void residual urine, water cystometry (with a ®lling rate of 50 ml/min), and a simultaneous pressure-¯ow study with a 7F urethral catheter. These assessments were carried out between 9.00 and 11.00 in the morning; patients were asked to attend for evaluation with a strong urge to void and a full bladder. The methods used conformed to the standards of the International Continence Society. Prostatic volume and post-void residual volume were assessed by transrectal and transabdominal ultrasound, respectively.
Statistics
Statistical calculations were made using Student's paired t-test with a 0.05 threshold of signi®cance.
Results
There was no signi®cant difference between the two treatment groups at baseline in age and duration of BPH. The mean age of patients in the treatment group was 62.1 (52 ± 78) y, while the mean age of the control group was 62.9 (53 ± 78) y. The mean duration of BPH in both groups was 19.31 (3 ± 84) months.
Treatment with Permixon 1 resulted in a signi®cant improvement in symptoms from baseline: I-PSS total score decreased by 26.8% from a baseline of 8.2 (s.e. 0.6, P`0.001) and the quality of life (QoL) score decreased by 18.2% from a baseline of 3.3 (s.e. 0.2, P`0.001; Table 1 ).
Q max increased by 6.0% ( 0.7 ml/s) from a baseline value of 11.7 (s.e. 0.4 ml/s, P`0.001) in the Permixon 1 group. The volume of residual urine in this group also decreased by 12.6% from a baseline value of 49.4 (s.e. 4.1 ml, P`0.05). Decrease in mean prostate volume after Permixon 1 treatment ( 7 1.6 ml) did not reach statistical signi®cance.
After 9 weeks there was no signi®cant difference in mean I-PSS score, QoL score, Q max , or residual volume in the control group. Mean prostate volume increased by 0.5 ml in these patients.
In patients receiving Permixon 1 there was a signi®cant decrease of 12.6% from baseline (59.4 (s.e. 3.6 cmH 2 O, P`0.001)) in detrusor opening pressure and of 12.8% from baseline (73.3 (s.e. 5.5 cmH 2 O, P`0.001)) in DP at maximum¯ow. Maximum DP also decreased, a reduction which was close to statistical signi®cance (5.2% reduction from a baseline of 82.5 (s.e. 5.7 cmH 2 O, P 0.06); Table  2 ). The improvement in these urodynamic parameters was accompanied by an increase in maximum urinarȳ ow (Figure 1) . Changes in the control group did not reach statistical signi®cance for any of these urodynamic parameters.
No statistical analyses were carried out to compare the treatment and control groups since the aim of this pilot study was simply to provide a rationale for a further double-blind, randomised study.
Three patients receiving Permixon 1 reported mild gastrointestinal disturbances. These were non-serious and additional medication or interruption of therapy was not required.
Discussion
Permixon 1 therapy produced a rapid and signi®cant improvement in the majority of urodynamic and symptomatic assessments carried out in this study. There were signi®cant reductions in the I-PSS and QoL scores, which were accompanied by signi®cant improvements in two urodynamic parameters: DP at maximum¯ow and DP opening pressure. Considered together with the signi®-cant improvement in Q max and residual urine, these data con®rm that Permixon 1 produced an improvement in IVO. There were no signi®cant improvements for any of these parameters in the control group despite the fact that both groups were comparable at baseline. The rapid improvement in IVO seen with Permixon 1 con®rms the positive effects of the drug on urinary function and this may be mainly due to its anti-in¯ammatory and antioedematic action. Although this was an open-label study, the degree of improvement in the test parameters suggests that Permixon 1 may have greater ef®cacy when evaluated under well-controlled conditions in patients Data are presented as mean ( AE standard error (s.e.)). *Signi®cant change from baseline (P`0.05). **Signi®cant change from baseline (P`0.001). with BPH, especially after prolonged use, 16 and further investigations, including urodynamic assessments, should be performed to con®rm our ®ndings.
Only three patients receiving Permixon 1 reported adverse events but these were mild gastrointestinal disturbances, which did not require additional medication. This is in line with other studies of Permixon 1 which have shown that the drug is well tolerated and does not adversely affect sexual function, unlike a competitive 5a-reductase (type 2) inhibitor. 16 Previous studies on the clinical ef®cacy of Permixon 1 have demonstrated that it improves symptoms,¯ow rates and volume of residual urine. 17, 18 Our results are in accordance with these ®ndings and comparable to improvements in urodynamic parameters demonstrated in studies of other ®rst-line treatments for BPH. 19, 20 In addition, a recent long-term study of a 5a-reductase type 2 inhibitor found that DP at maximum¯ow decreased continuously over 2 y (by 5.3 and 11.7 cmH 2 O at years 1 and 2, respectively. 21 In the current study, Permixon 1 (which inhibits 5a-reductase type 1 and type 2 enzymes) produced a 9.4 cmH 2 O decrease in DP at maximum¯ow after 9 weeks of treatment.
In contrast to our ®ndings, a previous study which included 50 men with LUTS suggestive of BPH found that another commercially available Saw palmetto (Serenoa repens) extract did not have a signi®cant effect on urodynamic parameters. 22 However, plant extracts may differ in composition according to their method of manufacture. Due to this variation, the recommendations of the 4th International Consultation on BPH state that the ef®cacy of each brand of plant extract should be studied individually. 4 The results of the current study therefore support the conference recommendations as they demonstrate that another Serenoa repens extract (Permixon 1 ) produces a signi®cant improvement in IVO as determined by urodynamic measurements.
Symptomatology is often used to make treatment decisions in BPH, despite the fact that there is relatively little published evidence de®ning the link between LUTS and IVO. In a recent large-scale study of patients with LUTS indicative of obstruction, symptoms alone (as measured by the International Continence Society ICS male questionnaire) were not suf®cient to diagnose IVO. It was concluded that urodynamic pressure-¯ow studies measure different clinical aspects of BPH. 23 Our ®ndings for Permixon 1 are supported by both urodynamic and symptomatic measures and demonstrate a considerable improvement in IVO over 9 weeks. In the future, longerterm urodynamic studies will enable further assessment of this therapeutic effect.
Conclusion
Treatment of BPH patients with Permixon 1 produced a rapid improvement in urodynamic parameters and symptoms, illustrating a reduction in infravesical obstruction. These data demonstrate that Permixon 1 is well tolerated and support its ef®cacy as ®rst-line medical therapy in patients with uncomplicated symptomatic BPH. 
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